V-Joy Biotechnology

V-Joy Biotechnology is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative gene therapies. The company leverages its proprietary AAV vector platform, which includes advanced capsid engineering and promoter optimization technologies, to target inherited and chronic diseases. Its lead candidate, VJ-001, is an AAV-based gene therapy for Leber congenital amaurosis type 2 (LCA2) caused by RPE65 mutations. V-Joy is also expanding its pipeline into other ophthalmic conditions like age-related macular degeneration and broader indications in the central nervous system and metabolic sectors. The company aims to provide one-time curative treatments for patients with high unmet medical needs.